Skip to main content

Hostile Social Interactions May Increase Inflammation

January 31, 2012 — Negative social interactions may increase proinflammatory cytokine reactivity, new research suggests. When chronic, this reactivity has been associated with hypertension, diabetes, coronary heart disease, depression, and some cancers.
In a prospective study of more than 100 healthy young adults, stressful or "hostile" interactions during daily living were associated with increased levels of the cytokines IL-6 and soluble receptor for tumor necrosis factor-α (sTNFαRII).
Significant levels of increased inflammation were also found after the participants engaged in competitive interactions, such as in school, the workplace, or even for another's attention, but not in leisure-time activities such as sports.
"Our findings about negative and competitive interactions were pretty much what we expected. But when we broke down the types of competitive activities, we were surprised that leisure activities didn't fall into this heightened inflammation group," lead author Jessica Chiang, doctoral student in health psychology at the University of California, Los Angeles, told Medscape Medical News.

Jessica Chiang

She noted that having a few of these negative or competitive social interactions "is not going to be detrimental to health." However, if these interactions are experienced day in and day out, they can add to a patient's stress burden.
"Interpersonal stressors are a very common form of stress in people's lives. So it would be advisable to have clinicians ask their patients about these stressors, and to tell patients that they should reevaluate how they deal with these situations," said Chiang.
The study was published online January 23 in Proceedings of the National Academy of Science (PNAS).
Real-World Study
According to investigators, previous research has shown that social relationships and physical health are interrelated.
"People who are more socially integrated live longer and are less likely to experience specific disease outcomes, including heart attacks and upper respiratory illness," they write.
Inflammation is a "natural, early response of the immune system that is essential to fighting infections and repairing injured tissue." Proinflammatory cytokines act as communication molecules during the inflammatory process.
Although acute inflammation is not a cause for concern, chronic reactivity can lead to several adverse health outcomes.
"Most of these types of studies have looked at negative or positive interactions and their possible relation to physical health. But there hasn't been a lot of work looking at competitive interactions," said Chiang.
"It was also important for us to take the study outside of the lab because many of the past studies have been conducted within the lab. Although that adds a lot to the literature, we wanted to see if we could find these same effects in everyday life."
The investigators enrolled 122 healthy students and employees from a large university (56.5% women; 61.5% Asian American; 38.5% European American). None were taking any cardiovascular, neuroendocrine, or mental health medications.
All participants filled out diaries for 8 days about the positive, negative, and competitive interactions they experienced. Within the first 4 days, they reported to a laboratory to fill out health questionnaires and undergo the Trier Social Stress Test (TSST).
Oral mucosal transudate samples were collected to assess levels of IL-6 and sTNFαRII at baseline and at 25 minutes and 80 minutes after the TSST stressor was given.
In addition to hypothesizing that both negative and competitive interactions would elevate cytokine responses to the laboratory stressors, the investigators predicted that positive interactions would reduce cytokine responses.
Deleterious Over Time
At baseline, elevations in the level of sTNFαRII was significantly associated with both negative social interactions (P = .014) and competitive interactions (P = .050). The relationship between elevated IL-6 levels and competitive interactions approached significance (P = .054).
At the 25-minute post-stressor point, negative social interactions predicted higher levels of both IL-6 (P = .032) and sTNFαRII (P = .043). However, competitive social interactions were not found to be significantly related to "stress-induced reactivity" at that time point.
"Although positive interactions were not correlated with any cytokine measure, in analyses that controlled for baseline, [the] interactions were related to higher sTNFαRII 25-minutes post-stressor" (P = .034), report the investigators, adding that that did not match their original hypothesis.
Still, "it is possible that this finding is not reliable," they write.
Negative social interactions significantly predicted total output of sTNFαRII (P = .021), whereas competitive interactions predicted total output of both sTNFαRII (P = .037) and IL-6 (P = .035). Positive interactions were not found to predict total output of either cytokine.
In further analyses, the researchers divided competitive interactions into 3 subcategories: leisure (including sports), academic- or work-related, and competing for a friend's or loved one's attention.
Academic- or work-related competitive activities significantly predicted baseline levels of sTNFαRII (P = .026), and competing for attention significantly predicted baseline levels of IL-6 (P = .014). Leisure activities/sports were not significantly related to any of the cytokine measures.
"This could be because leisure activities are often seen as more challenging, not threatening. But the stakes seem much higher when it comes to school, work, or gaining attention. Wondering 'what does my boss think of me?' could be a blow to the ego or self-esteem," explained Chiang."
The researchers note that although some inflammation can be beneficial, repeated activation is "deleterious" over time.
"Thus, cumulatively, a greater number of daily negative and competitive social interactions may…predict inflammation-related disorders and exacerbate existing illnesses," they write. "This is an important direction for future research."
Chiang notes that she hopes the next step is to "dig deeper and find out 'what is the quality of these relationships that people are having?' And then find out if that predicts inflammation as well."
The study was supported by the National Institute on Aging and the National Science Foundation. The study authors have disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Sitting at Work Raises All-Cause and CV Mortality Risk

May 21, 2012 (Lyon, France) — Sitting at work raises the risk of dying from cardiovascular (CV) and metabolic diseases, as well as the risk of dying from all causes, regardless of any exercise in which the individual may engage. That was the finding of a study reported here at the 19th European Congress on Obesity (ECO) by Anne Grunseit, PhD, from the Prevention Research Collaboration in the School of Public Health at the University of Sydney, Australia, and Norwegian colleagues. Research is increasingly focusing on sedentary behavior with low energy expenditure, including sitting and lying down, as behavioral risk factors for obesity and chronic disease. Sitting occurs during travel, while watching television, using computers, and reading. But with people often spending at least 9 hours a day at work, with fewer than 20% of jobs requiring physical exertion, and with many people spending at least 4 hours a day sitting at work, the sedentary time at work is high, and many people ar...